1.04 USD
▼+0.10-1.89%
盘后 1.07 +1.30%
2026-08-03
市值
$46.90M
市盈率
—
EPS
-0.33
股息率
—
52 周区间
0.70 – 1.45
成交量
401.84K
Beta
0.99
目标价
7.03
52W 低 0.7052W 高 1.45
价格走势
公司简介
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.